The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.
The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.
AMSTERDAM — The monoclonal antibody bimekizumab (Bimzelx ... over time with the first FDA-approved class of biologics for ...
Big news out of New Jersey this morning as a %Biotech company said it received “positive feedback” from the European ...
Innovent Biologics (IVBXF) announced the latest clinical results of a multicenter, open-label Phase 2 study of picankibart, a recombinant ...
BRIDGEWATER, NJ / ACCESSWIRE / November 4, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic ...
The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for Alvotech and Advanz Pharma’s ...
Head of Investor Relations Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual ...
November 04, 2024 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...
At the core of this project are the cells, which will be genetically engineered to produce antibodies in response to TNF-alpha, a protein associated with IBD symptom flare-ups. Alexander Revzin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback